Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink

IMPORTANCE: Postauthorization monitoring of vaccines in a large population may detect rare adverse events not identified in clinical trials such as Guillain-Barré syndrome (GBS), which has a background rate of 1 to 2 per 100 000 person-years. OBJECTIVE: To describe cases and incidence of GBS followi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanson, Kayla E., Goddard, Kristin, Lewis, Ned, Fireman, Bruce, Myers, Tanya R., Bakshi, Nandini, Weintraub, Eric, Donahue, James G., Nelson, Jennifer C., Xu, Stan, Glanz, Jason M., Williams, Joshua T. B., Alpern, Jonathan D., Klein, Nicola P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044108/
https://www.ncbi.nlm.nih.gov/pubmed/35471572
http://dx.doi.org/10.1001/jamanetworkopen.2022.8879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044108/
https://www.ncbi.nlm.nih.gov/pubmed/35471572
http://dx.doi.org/10.1001/jamanetworkopen.2022.8879

Ejemplares similares